Cargando…
Drug induced interstitial lung disease in oncology phase I trials
Interstitial lung disease is a serious drug‐related condition that can cause life threatening organ failure. The incidence and risk factors of drug‐induced interstitial lung disease (DILD) are unknown in oncology phase I trials. This study analyzed clinical information from 8906 patients with malign...
Autores principales: | Yonemori, Kan, Hirakawa, Akihiro, Kawachi, Asuka, Kinoshita, Fumie, Okuma, Hitomi, Nishikawa, Tadaaki, Tamura, Kenji, Fujiwara, Yasuhiro, Takebe, Naoko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5198943/ https://www.ncbi.nlm.nih.gov/pubmed/27685762 http://dx.doi.org/10.1111/cas.13087 |
Ejemplares similares
-
Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose‐finding trials
por: Hirakawa, Akihiro, et al.
Publicado: (2017) -
Content Analysis of Oncology-Related Pharmaceutical Advertising in a Peer-Reviewed Medical Journal
por: Yonemori, Kan, et al.
Publicado: (2012) -
Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population
por: Noda-Narita, Shoko, et al.
Publicado: (2019) -
First-line treatment for lung cancer among Japanese older patients: A real-world analysis of hospital-based cancer registry data
por: Noda-Narita, Shoko, et al.
Publicado: (2021) -
Use of Cox's Cure Model to Establish Clinical Determinants of Long-Term Disease-Free Survival in Neoadjuvant-Chemotherapy-Treated Breast Cancer Patients without Pathologic Complete Response
por: Asano, Junichi, et al.
Publicado: (2013)